Studies on Endocrine Therapy for Endometriosis

GnRH激动剂和那那唑可用于治疗子宫内膜异位症患者。这些化合物可诱导子宫内膜异位症的萎缩和消退，但其作用机制尚不清楚。因此，本研究旨在阐明这些化合物在治疗子宫内膜异位症中的作用机制。此外，还评估了这些化合物对子宫内膜异位症的联合治疗。以实验性雌性大鼠子宫内膜异位症为例，考察了这些化合物的作用。在实验性子宫内膜异位症中，联合治疗（16/17）在诱导液体萎缩和消退方面优于那那唑（9/20）或GnRH激动素（14/24）。使用GnRH激动剂可降低血清雌二醇水平，但使用那那唑无此作用。研究结果表明，GnRH激动剂和达那唑的联合治疗，表现出不同的作用模式，可能是治疗子宫内膜异位症患者的潜在模式。一项临床试验是为了检查GnRH激动剂和那那唑的联合治疗是否对子宫内膜异位症有用。联合用药诱导子宫内膜异位症萎缩的效果优于单纯GnRH激动剂或那那唑。联合治疗在子宫内膜异位症患者中的潜在应用应通过大规模的临床试验进行评估。

GnRH agonist and danazol are useful for treatment of patients with endometriosis. These compounds induce atrophy and regression of endometriosis, but the action mechanisms are still unclear. The present study, therefore, was undertaken to elucidate the mechanisms of these compounds in the treatment of endometriosis. In addition, a combination therapy with these compounds for endometriosis was also evaluated. With use of experimental endometriosis of female rats, the effects of these compounds were examined. The combination therapy (16/17) was shown to be superior to danazol (9/20) or GnRH agonistalone (14/24) to induce atrophy and regression of fluid in experimental endometriosis. Administration of GnRH agonist decreased serum estradiol level, but use of danazol did not. The findings suggest that a combination therapy of GnRH agonist and danazol, which show different mode of action, may be a potential modelity in treatment of patients with endometriosis.A clinical trial was initiated to examine whether the combination therapy of GnRH agonist and danazol is useful for endometriosis. The combination therapy was more effective to induce atrophy of endometriosis than GnRH agonist or danazol alone. The potential application of combination therapy in the treatment of patients with endometriosis should be evaluated with large scale clinical trials.